We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy

News   Nov 03, 2009

 
Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy
 
 
 

RELATED ARTICLES

Attacking RNA with Small-molecule Drugs

News

Yale researchers have developed a way to target RNA with small-molecule drugs, creating a new method for tapping into a vast number of biological mechanisms critical to metabolism and gene expression.

READ MORE

Being Organized Maintains Immune Heath

News

Immune health is maintained by the exquisite organisation skills of a protein called Pax5.

READ MORE

Having a Heavier First-Born or Shorter Pregnancy May Increase Mother’s Breast Cancer Risk

News

Short first pregnancies and having a heavier first-born child may slightly increase a mother’s risk of breast cancer, a new study has found.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE